We generated a library of ~1000 stocks in which we inserted a construct in the intron of genes allowing expression of under control of endogenous promoters while arresting transcription with a polyadenylation signal 3' of the GAL4. This allows numerous applications. First, ~90% of insertions in essential genes cause a severe loss-of-function phenotype, an effective way to mutagenize genes. Interestingly, 12/14 chromosomes engineered through CRISPR do not carry second-site lethal mutations. Second, 26/36 (70%) of lethal insertions tested are rescued with a single cDNA construct. Third, loss-of-function phenotypes associated with many insertions can be reverted by excision with . Fourth, driven reports tissue and cell-type specificity of gene expression with high sensitivity. We report the expression of hundreds of genes not previously reported. Finally, inserted cassettes can be replaced with or any DNA. These stocks comprise a powerful resource for assessing gene function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898912 | PMC |
http://dx.doi.org/10.7554/eLife.35574 | DOI Listing |
Methods Mol Biol
November 2024
Faculty of Agriculture, Ryukoku University, Shiga, Japan.
DeLTa-seq is a high-throughput RNA-seq library preparation method that enables quantification of the expression of hundreds of arbitrarily selected genes without RNA purification. This method involves direct reverse transcription using rice leaf lysate and targeted RNA-seq library preparation. DeLTa-seq enables the precise quantification of gene expression with a small number of sequencing reads.
View Article and Find Full Text PDFAm J Physiol Cell Physiol
December 2024
Department of Physiology/Biophysics, School of Medicine, University of California, Irvine, California, United States.
The human colonic thiamin pyrophosphate transporter (hcTPPT) mediates the uptake of the microbiota-generated and phosphorylated form of vitamin B (i.e., thiamin pyrophosphate) in the large intestine.
View Article and Find Full Text PDFDiagnostics (Basel)
August 2024
Georgia Esoteric and Molecular Biology Laboratory, Department of Pathology, Augusta University, Augusta, GA 30912, USA.
Background: Multidrug-resistant HIV strains challenge treatment efficacy and increase mortality rates. Next-generation sequencing (NGS) technology swiftly detects variants, facilitating personalized antiretroviral therapy.
Aim: This study aimed to validate the Vela Diagnostics NGS platform for HIV drug resistance mutation analysis, rigorously assessed with clinical samples and CAP proficiency testing controls previously analyzed by Sanger sequencing.
PLoS One
August 2024
Department of Microbiology, The Catholic University of Korea, Seoul, Korea.
Single-cell RNA sequencing (scRNA-seq) has emerged as a versatile tool in biology, enabling comprehensive genomic-level characterization of individual cells. Currently, most scRNA-seq methods generate barcoded cDNAs by capturing the polyA tails of mRNAs, which exclude many non-coding RNAs (ncRNAs), especially those transcribed by RNA polymerase III (Pol III). Although previously thought to be expressed constitutively, Pol III-transcribed ncRNAs are expressed variably in healthy and disease states and play important roles therein, necessitating their profiling at the single-cell level.
View Article and Find Full Text PDFChirurgie (Heidelb)
September 2024
Klinik und Poliklinik für Allgemein‑, Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland.
Background: Lynch syndrome (LS) is the most frequent hereditary tumor syndrome and is associated with an increased risk of colorectal cancer (CRC). While gene-specific and age-specific differences are considered in patient surveillance, gender-specific risks in the development of CRC have been reported in many studies but are not consistently documented.
Objective: This systematic review aims to investigate gender-specific differences in CRC development among LS patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!